Johnson & Johnson (NYSE:JNJ) is Clark & Stuart Inc’s 3rd Largest Position

Clark & Stuart Inc lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 52,462 shares of the company’s stock after selling 412 shares during the quarter. Johnson & Johnson comprises approximately 6.3% of Clark & Stuart Inc’s portfolio, making the stock its 3rd biggest position. Clark & Stuart Inc’s holdings in Johnson & Johnson were worth $8,700,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in JNJ. MRP Capital Investments LLC lifted its stake in Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock valued at $237,000 after buying an additional 65 shares in the last quarter. Syverson Strege & Co lifted its stake in Johnson & Johnson by 4.9% in the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after buying an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management lifted its stake in Johnson & Johnson by 3.3% in the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock valued at $301,000 after buying an additional 66 shares in the last quarter. Denali Advisors LLC lifted its stake in Johnson & Johnson by 1.3% in the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock valued at $742,000 after buying an additional 67 shares in the last quarter. Finally, Sage Mountain Advisors LLC lifted its stake in Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company’s stock valued at $2,106,000 after buying an additional 67 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.6%

JNJ stock opened at $149.81 on Friday. The firm has a market cap of $360.44 billion, a PE ratio of 16.66, a PEG ratio of 2.28 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm’s 50 day moving average price is $154.07 and its 200-day moving average price is $153.63. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.47%. Johnson & Johnson’s payout ratio is presently 57.84%.

Analyst Ratings Changes

A number of research analysts recently weighed in on JNJ shares. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 16th. Leerink Partnrs lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Finally, Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.